ABSTRACT
This chapter describes trade name, classification, approved Indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, and clinically significant drug interactions of Thioproperazine. Safety and efficacy of thioproperazine pharmacotherapy for women who are breast-feeding and their neonates and infants have not been established. Avoid prescribing thioproperazine pharmacotherapy to women who are breast-feeding. Prescribe general or discontinuous thioproperazine pharmacotherapy according to the patient’s signs and symptoms of psychosis and previous response to antipsychotic pharmacotherapy. Thioproperazine is a potent antipsychotic that has cataleptic and antiemetic actions. It also has mild sedative, hypothermic, and spasmolytic actions. Concurrent alcohol use may increase the CNS depressant action of thioproperazine. Advise patients to avoid, or limit, their use of alcohol while receiving thioproperazine pharmacotherapy. Concurrent thioproperazine pharmacotherapy with opiate analgesics, sedative-hypnotics, or other drugs that produce CNS depression may result in additive CNS depression.
